AU2016260895B2 - Treatment for multiple myeloma (MM) - Google Patents

Treatment for multiple myeloma (MM) Download PDF

Info

Publication number
AU2016260895B2
AU2016260895B2 AU2016260895A AU2016260895A AU2016260895B2 AU 2016260895 B2 AU2016260895 B2 AU 2016260895B2 AU 2016260895 A AU2016260895 A AU 2016260895A AU 2016260895 A AU2016260895 A AU 2016260895A AU 2016260895 B2 AU2016260895 B2 AU 2016260895B2
Authority
AU
Australia
Prior art keywords
seq
sequence
antibody
region
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016260895A
Other languages
English (en)
Other versions
AU2016260895A1 (en
Inventor
Jan Endell
Stefan HÄRTLE
Stéphane LECLAIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys GmbH
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of AU2016260895A1 publication Critical patent/AU2016260895A1/en
Application granted granted Critical
Publication of AU2016260895B2 publication Critical patent/AU2016260895B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
AU2016260895A 2015-05-13 2016-05-13 Treatment for multiple myeloma (MM) Active AU2016260895B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15167597 2015-05-13
EP15167597.2 2015-05-13
PCT/EP2016/060810 WO2016180958A1 (en) 2015-05-13 2016-05-13 Treatment for multiple myeloma (mm)

Publications (2)

Publication Number Publication Date
AU2016260895A1 AU2016260895A1 (en) 2017-11-09
AU2016260895B2 true AU2016260895B2 (en) 2021-08-05

Family

ID=53174925

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016260895A Active AU2016260895B2 (en) 2015-05-13 2016-05-13 Treatment for multiple myeloma (MM)

Country Status (24)

Country Link
US (2) US10533057B2 (2)
EP (1) EP3294769B1 (2)
JP (2) JP7160533B2 (2)
KR (1) KR20180008571A (2)
CN (1) CN107614530A (2)
AU (1) AU2016260895B2 (2)
CA (1) CA2984464C (2)
CY (1) CY1123982T1 (2)
DK (1) DK3294769T3 (2)
ES (1) ES2862708T3 (2)
HR (1) HRP20210552T1 (2)
HU (1) HUE054271T2 (2)
IL (1) IL255552B (2)
LT (1) LT3294769T (2)
MX (1) MX380557B (2)
PL (1) PL3294769T3 (2)
PT (1) PT3294769T (2)
RS (1) RS61668B1 (2)
RU (1) RU2723047C2 (2)
SG (1) SG11201708691VA (2)
SI (1) SI3294769T1 (2)
SM (1) SMT202100202T1 (2)
WO (1) WO2016180958A1 (2)
ZA (1) ZA201708386B (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
HUE054271T2 (hu) * 2015-05-13 2021-08-30 Morphosys Ag Mielóma Multiplex (MM) kezelése
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
CN110144008B (zh) 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
KR20250117714A (ko) * 2018-03-28 2025-08-05 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투약
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
KR20210104736A (ko) * 2018-12-14 2021-08-25 모르포시스 아게 항체 제형
JP7712206B2 (ja) * 2019-01-28 2025-07-23 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法
WO2020194242A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with pomalidomide and dexamethasone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041800A1 (en) * 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
AU2007281684C1 (en) * 2006-08-07 2013-12-19 Abbvie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
WO2008037257A2 (en) * 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
SMT202000031T1 (it) * 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
US9738933B2 (en) * 2012-12-05 2017-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS
CN103421115B (zh) * 2013-09-02 2015-06-03 东南大学 一种cd38纳米抗体及应用
US20150118251A1 (en) * 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
WO2016022589A2 (en) * 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
PH12017500442B1 (en) 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
HUE054271T2 (hu) * 2015-05-13 2021-08-30 Morphosys Ag Mielóma Multiplex (MM) kezelése

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041800A1 (en) * 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl

Also Published As

Publication number Publication date
RU2017137496A3 (2) 2019-06-13
WO2016180958A1 (en) 2016-11-17
US11591406B2 (en) 2023-02-28
US20190048091A1 (en) 2019-02-14
DK3294769T3 (da) 2021-03-08
SI3294769T1 (sl) 2021-07-30
SMT202100202T1 (it) 2021-05-07
EP3294769B1 (en) 2021-01-13
US10533057B2 (en) 2020-01-14
JP2018515513A (ja) 2018-06-14
US20200079871A1 (en) 2020-03-12
CN107614530A (zh) 2018-01-19
CY1123982T1 (el) 2022-05-27
MX380557B (es) 2025-03-12
HRP20210552T1 (hr) 2021-05-14
PT3294769T (pt) 2021-04-13
RU2017137496A (ru) 2019-06-13
JP7160533B2 (ja) 2022-10-25
RU2723047C2 (ru) 2020-06-08
ZA201708386B (en) 2019-06-26
KR20180008571A (ko) 2018-01-24
IL255552A (en) 2018-01-31
HUE054271T2 (hu) 2021-08-30
JP2021130668A (ja) 2021-09-09
PL3294769T3 (pl) 2021-07-05
IL255552B (en) 2022-01-01
ES2862708T3 (es) 2021-10-07
RS61668B1 (sr) 2021-04-29
LT3294769T (lt) 2021-04-26
AU2016260895A1 (en) 2017-11-09
EP3294769A1 (en) 2018-03-21
CA2984464C (en) 2023-10-10
SG11201708691VA (en) 2017-11-29
MX2017014396A (es) 2018-03-23
CA2984464A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
AU2016260895B2 (en) Treatment for multiple myeloma (MM)
AU2018278327B2 (en) Activatable anti-pdl1 antibodies and methods of use thereof
JP6499971B2 (ja) 抗ｃｄ３８抗体及びレナリドマイドを含む組成物
AU2013322806B2 (en) Combinations and uses thereof
EP2849784A1 (en) Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
CN118949031A (zh) 用gm-csf拮抗剂治疗癌症
WO2023172906A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
KR20240117655A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
TW202547859A (zh) 抗人類pd-l1抗體及其用途
HK1247939A1 (en) Treatment for multiple myeloma (mm)
EA051578B1 (ru) Терапия анти-cd19 в комбинации с леналидомидом для лечения лейкоза или лимфомы
CA3064588A1 (en) Activatable anti-pdl1 antibodies, and methods of use thereof
HK1210949B (zh) 组合及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)